IDM Obtains a European Patent Protecting the Basic Technology Behind its Therapeutic Vaccines.
These vaccines are designed to prevent tumor relapse. They come from the patient's white blood cells, exposed to IL-13 and GM-CSF, biological compounds which contribute to their transformation into dendritic cells. These dendritic cells are then exposed to tumor antigens and reinjected into the patient to stimulate the immune system's ability to recognize and destroy tumor cells which express this antigen on their surfaces.
IDM's most advanced product in this class is called Uvidem(R). It is being developed in partnership with Sanofi-Aventis for the treatment of melanoma. Another therapeutic vaccine, Collidem(R), is in clinical development in the United States for colorectal cancer.
The patent granted to IDM by the European Patent Office is titled "New antigen presenting cells, a process for preparing the same and their use as cellular vaccines". It covers the preparation process and the dendritic cells obtained after differentiation of the monocytes from the blood.
IDM's patent portfolio includes 141 proprietary patents issued and granted (including 23 issued in the United States) and 86 patents pending (including 22 in the United States). Additionally, IDM has exclusive rights to 92 issued and granted patents which it has in-licensed.
To date, more than 96% of IDM's shareholders have entered into a definitive agreement to combine IDM with Nasdaq publicly traded Epimmune Inc. in an all-stock transaction expected to close in the second or third quarter of 2005. Epimmune has filed a proxy statement with the United States Securities and Exchange Commission in connection with the transaction, which is subject to approval by the Epimmune stockholders and certain other closing conditions.
IDM is a biopharmaceutical company focused on the development of innovative products to treat and control cancer while maintaining the patient's quality of life. IDM is currently developing two lines of products: one aiming at the destruction of residual cancer cells after the use of traditional therapies, and the other to prevent tumor recurrence by triggering an immune response. IDM's most advanced product has completed a Phase III clinical trial, five other products are in clinical trials and five are in preclinical development. For more information, visit http://www.idm-biotech.com/.
Where You Can Find Additional Information About IDM's Proposed Combination with Epimmune
Epimmune Inc. has filed a preliminary proxy statement concerning its proposed combination with IDM with the Securities and Exchange Commission (SEC). Investors and security holders are advised to read the proxy statement related to the proposed transaction because it contains important information related to the transaction. Investors and security holders may obtain a free copy of the proxy statement and other documents filed by Epimmune with the SEC at the SEC's website at http://www.sec.gov/. The proxy statement and any other documents filed by Epimmune with the SEC may also be obtained free of charge from Epimmune by directing such request to Epimmune's Secretary at the following address: 5820 Nancy Ridge Drive, San Diego, California 92121.
Information Concerning Participation in Epimmune's Proxy Solicitation
IDM and Epimmune and their respective executive officers and directors may be deemed to be participants in the solicitation of proxies from the stockholders of Epimmune with respect to the proposed transaction between Epimmune and IDM. Information regarding Epimmune's executive officers and directors is included in Epimmune's Annual Report on Form 10-K filed with the SEC for the year ended December 31, 2004. This document is available free of charge at the SEC's website at http://www.sec.gov/ and from Epimmune at http://www.epimmune.com/. Investors and security holders may obtain additional information about the interests of the respective executive officers and directors of Epimmune and IDM in the proposed transaction between Epimmune and IDM by reviewing the proxy statement related to the transaction filed with the SEC.
Contact IDM: Nadine Sciacca, Director of Communications Tel.: +33-1-40-09-04-11 E-mail: firstname.lastname@example.org Euro RSCG C&0: Marie-Carole de Groc/Florence Macaire +33-1-58-47-95-07/+33-1-58-47-95-18 email@example.com firstname.lastname@example.org
CONTACT: IDM: Nadine Sciacca, Directeur Communication, Tel.: +33-1-40-09-04-11, E-mail: email@example.com. Euro RSCG C&0: Marie-Carole de Groc/Florence Macaire, +33-1-58-47-95-07/+33-1-58-47-95-18, firstname.lastname@example.org, email@example.com
|Printer friendly Cite/link Email Feedback|
|Date:||May 24, 2005|
|Previous Article:||EMC Announces New Generation of Content Classification Software.|
|Next Article:||Encinal Jackson LLC Selects Autonomy's Idol Server for Litigation Support and Information Retrieval.|